Clinical trial · Interventional
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy
NCT01990534CI-TRIAL-00051182completedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This phase 4, single-arm, open-label, multicenter study is designed to evaluate the efficacy and safety of brentuximab vedotin as a single agent in adult participants with histologically confirmed CD30+ relapsed or refractory classical Hodgkin Lymphoma who have not received a prior stem cell transplantation (SCT) and are considered to be not suitable for SCT or multiagent chemotherapy at the time of study entry.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brentuximab Vedotin | Drug | Brentuximab Vedotin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Brentuximab Vedotin 1.8 mg/kg
- description
- Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
- interventionNames
- Drug: Brentuximab Vedotin
Primary outcomes (1)
- measure
- Objective Response Rate (ORR)
- timeFrame
- Baseline until disease progression, death or end of study (EOS) (Up to 24 months)
- description
- Objective response rate is defined as the percentage of participants with complete remission (CR) or partial remission (PR) as assessed by an independent review facility (IRF) using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
Secondary outcomes (12)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Each participant must meet all of the following inclusion criteria to be enrolled in the study: 1. Male or female participants 18 years or older, with relapsed or refractory classical Hodgkin lymphoma (HL), who have previously received at least 1 prior systemic chemotherapeutic regimen 2. Not suitable for stem cell transplantation (SCT) or multiagent chemotherapy, according to 1 of the following criteria: * Disease progression within 90 days of the earliest date of complete remission (CR) or complete remission unconfirmed (CRu) after the end of treatment with multiagent chemotherapeutic regimens and/or radiotherapy * Progressive disease during frontline multiagent chemotherapy * Disease relapse after treatment with at least 2 chemotherapeutic regimens, including any salvage treatments 3. Bidimensional measurable disease 4. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 5. Female participants who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception at the same time, or agree to practice true abstinence. 6. Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence. 7. Clinical laboratory values as specified in the study protocol. Exclusion Criteria: Participants who meet any of the following exclusion criteria are not to be enrolled in the study: 1. Previous treatment with brentuximab vedotin 2. Previously received an autologous stem cell transplantation (ASCT) or alloSCT 3. Known cerebral/meningeal disease, including signs or symptoms suggestive of progressive multifocal leukoencephalopathy (PML), or any history of PML. 4. Female participants who are lactating and breastfeeding or pregnant. 5. Known human immunodeficiency virus (HIV). 6. Known hepatitis B surface antigen positive, or known or suspected active hepatitis C infection. 7. Grade 2 or higher peripheral neuropathy.
References
Publications (0)
Data not yet available
No reference posted for this study.